The size of the plasma fractionation market in the Middle East & Africa is estimated to be USD 2.32 billion in 2022. It is projected to be growing at a CAGR of 4.02% and worth USD 2.82 billion by 2027.
Plasma is the liquid portion of blood that consists of red cells, white cells, and platelets suspended in it and also contains thousands of various proteins and other substances like electrolytes, minerals, hormones, etc., which are necessary for the normal function of the human body.
Plasma Fractionation is the fractionation of blood into its constituent parts of red cells, white cells, and platelets, suspended in plasma. The plasma is studied for deficiencies relating to blood disorders and replaced or supplemented with a cure. Maintenance of blood pressure and the regulation of body temperature is among the vital functions of Plasma.
The growth of the Middle East and Africa Plasma Fractionation Market is mainly driven by the increasing occurrence of bleeding and immunity disorders related to blood, the rising use of albumin and immunoglobulins, and the growing aging population.
High costs of plasma products and the side-effects of plasma fractionation & plasma exchange are among the factors that hinder the growth of the Middle East and Africa plasma fractionation market.
This research report on the MEA plasma fractionation market has been segmented and sub-segmented into the following categories:
By End User:
KEY MARKET PLAYERS:
Some of the companies playing a key role in the MEA plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com